Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Rivastigmine to Prevent Recurrence of Antimuscarinic Delirium — Stella

Home/Anticholinergic Toxicity/Rivastigmine to Prevent Recurrence of Antimuscarinic Delirium

View on ClinicalTrials.gov

Recruiting

Back to Anticholinergic Toxicity trials

Rivastigmine to Prevent Recurrence of Antimuscarinic Delirium

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

Washington University School of Medicine, St Louis, Missouri

Key details

Phase

Safety & dosing

Sponsor

Washington University School of Medicine

Collaborators

American Academy of Clinical Toxicology

Enrollment target

~42 participants

Started

November 2024

Primary completion

October 2026

Age range

10 Years and older

Last updated July 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.